News

Clinical Advisor2h
FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid
The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.
FDA’s new approach raises questions about fall COVID vaccine availability
Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or ...
STAT4h
Investors unfazed by FDA’s Covid vaccine framework
The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...
FOX6 News Milwaukee4h
FDA will limit approval for seasonal COVID vaccines: What to know
Healthy younger adults and children will no longer be automatically approved for annual COVID-19 vaccines under a new policy from the FDA.
Insider Monkey4h
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target ...
Victoria Advocate5h
FDA Limits COVID-19 Boosters to Seniors, Other High-Risk Groups
WEDNESDAY May 21, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has decided that only seniors and ...
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...
BioSpace7h
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director ...